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Abstract  
 The use of antibiotics is necessary to treat bacterial diseases. Determination of 
optimal dosage in the target animals is increasingly being recognized as vital for maximizing 
efficacy and minimizing the risk of resistance, so this study aimed to evaluate the 
pharmacokinetics/pharmacodynamics (PK/PD) of levofloxacin in broilers. Using a parallel 
study design, each group of animals (n=20) received 5 mg/kg of levofloxacin intravenously 
(IV) and orally (PO). Plasma, serum and tissues were collected for PK and PD studies. 
Plasma concentrations of levofloxacin were determined by HPLC. Minimal inhibitory 
concentration (MIC) and minimal bactericidal concentration (MBC) were determined against 
E. coli, isolated in clinical broilers. Ex vivo antibacterial activity was evaluated using the time 
killing method. Mean values of terminal half-life for IV and PO groups were 6.93 and 8.09 h, 
respectively. Following oral administration, the peak plasma concentration was achieved at 
0.88 h (Tmax). Mean value of oral bioavailability was 123.25%. Levofloxacin residues were 
found in all the tissues tested (muscle, liver, kidney and lung). Plasma concentration above 8 
x MIC lead to eradication of E. coli (incubation period of 24h). The results of ex vivo growth 
inhibition curves were consistent with the in vitro time-kill study. Levofloxacin showed 
dependent plasma concentration antibacterial activity against a clinical isolate of E. coli. 
According to the assessment of PK/PD relationship, administration of 5 mg/kg of 
levofloxacin seems to be effective in killing E. coli. Also, simulated optimal dose based on 
the ex vivo PK/PD approach was 2.9 mg/kg/day (bactericidal) to 4.3 mg/kg/day (eradication) 
PO against E. coli (MIC = 0.125 µg/ml). 
 
Keywords: Levofloxacin; Pharmacokinetics; Pharmacodynamics; Broilers; Escherichia coli  
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Introduction 
The poultry industry has burgeoned in the last few decades (Landoni and Albarellos, 
2015). It produces meat and eggs, which are two of the most important food sources for 
humans and for dogs and cats. Farms are organized in cluster breed system, an intensive 
breeding technique that requires specific prevention and treatment strategies to prevent and 
manage infectious diseases. Effective prevention of infectious diseases is a critical goal for 
veterinarians, farm owners and poultry foodstuff consumers. 
 
Fluoroquinolones are widely used for the treatment of bacterial infections in both 
human and veterinary fields. Drugs belonging to this class are effective against a broad range 
of important poultry pathogens, including Escherichia coli, Salmonella spp. Mycoplasma, 
and Pasteurella spp. (Wolfson and Hooper, 1989; Janecko et al., 2016).  
 
Recently, the development of resistance to fluoroquinolones has been reported and 
become a debated issue among microbiologists, physicians and veterinarians (Brown, 1996; 
Nakamura, 1997; EFSA, 2012; WHO, 2012). The spread of bacterial resistance is mainly due 
to overuse and/or improper use of antibiotics: inappropriate dosage regimens or extra-label 
use can contribute to the development of bacterial resistance in animals and in humans. Thus, 
it has been suggested that the optimal dosing regimen should be determined to maximize the 
therapeutic efficacy and to minimize the risk of resistance emerging during treatments 
(Ambrose et al., 2007; Toutain and Lees, 2004). To achieve these goals, the optimal dosage 
of an antimicrobial drug must be evaluated using pharmacokinetic/pharmacodynamic (PK/PD) 
integration. 
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For antimicrobial drugs, there are three major PK/PD indices: maximal plasma 
concentration correlated to minimal inhibitory concentration (Cmax/MIC), area under the 
curve correlated to minimal inhibitory concentration (AUC/MIC), and the time over minimal 
inhibitory concentration (T > MIC), these are used as a basis for determining optimal dosage 
(Craig, 1998, Lees and Aliabadi, 2002). These parameters, especially Cmax/MIC and 
AUC/MIC, are the most significant predictors of the efficacy of fluoroquinolones and these 
indices have been extensively investigated in the veterinary field (McKellar et al., 2004). 
According to Thomas et al. (1998), a AUC24h/MIC ratio of 100 or greater is correlated to 
reduced selection for resistance. 
 
Levofloxacin is a third generation fluoroquinolone labelled for use in humans, and it 
has excellent anti-bacterial activity against gram-negative, gram-positive and anaerobic 
bacteria (North et al., 1998). Moreover, it is efficient against Streptococcus pneumoniae, 
most Enterococci, Enterobacteriaceae, Escherichia coli, Klebsiella, Proteus, Pseudomonas, 
Bacteroides, Clostridium, Haemophilus, Moraxella, Legionella,and Mycoplasma (Langtry 
and Lamb, 1998). Levofloxacin is extensively used in human medicine because has enhanced 
effects if compared to ciprofloxacin and ofloxacin. 
 
Although this antibacterial is not registered in veterinary medicine, several PK studies 
recently demonstrated that it could be successfully used in calves, goats and poultry (Dumka, 
2007; Goudah et al., 2009; Kumar et al., 2009; Ram et al., 2008; Varia et al., 2009). However, 
a PK/PD study of levofloxacin in broilers is lacking. Considering all these facts, this study 
aimed to: (a) evaluate PK and tissue disposition of levofloxacin after intravenous (IV) and 
oral (PO) administrations at the dose of 5 mg/kg in broilers, (b) to evaluate the drug 
disposition in different tissues, (c) to calculate the MIC and MBC of levofloxacin against E. 
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coli in two matrices (serum and broth), (d) to assess in vivo and ex vivo antibacterial effects 
of levofloxacin against E. coli using time kill experiment, (e) to predict the optimal doses 
corresponding to bacteriostatic, bactericidal and eradication effects based on AUC24h/MIC ex 
vivo parameter for PK/PD modelling.  
 
Material and methods 
Chemical and reagents 
Pure levofloxacin and enrofloxacin (used as internal standard –IS- ) with a standard 
purity >99.0%, were purchased from Sigma-Aldrich (Milan, Italy). HPLC-grade acetonitrile 
(ACN), methanol (MeOH), trichloromethane (CHCl3) and isopropanol (C3H8O) were 
purchased from Merck. Tetraethylamine was obtained from Sigma-Aldrich (Milan, Italy). 
Orthophosphoric acid, disodium hydrogenophosphate, sodium dihydrogen phosphate and 
potassium dihydrogenophosphate were purchased from Carlo Erba Reagents (Milan, Italy). 
Deionized water was produced by a Milli-Q Millipore Water System (Millipore, Milan, Italy). 
All the other reagents and materials were of analytical grade and were supplied by 
commercial sources. The aqueous and organic components of the mobile phase, degassed 
under pressure, were mixed by the HPLC. The LC mobile phases were filtered through 0.2 
μm cellulose acetate membrane filters (Sartorius Stedim Biotech, Goettingen, Germany) with 
a solvent filtration apparatus. 
 
Animal experiment 
Sixty-five healthy broiler chickens (Ross 308), 35 days old, with an average weight of 
2.2 ± 0.3 kg were supplied by a local farm and checked by a veterinarian (H.K.) who 
certificated the good health status, and the absence of recent drug treatment and parasites. 
Animals were acclimated for a 2-week period prior to beginning the study. During this period, 
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chickens were housed in a communal indoor area on the floor. Regular veterinary checks, 
based on daily physical examination through observation of behavior and appetite, assessed 
that animals were in good health. Animal care and handling were performed according to the 
EC council Directive 2010/63 and also according to Institutional Animal Care and Use 
directives issued by the Animal Welfare Committee of Latvia (authorization n° 025564), 
which approved the study design. The day before the commencement of the experiment, 
animals were randomly divided (65 slips of paper marked with the numbers 1 to 65 selected 
blinded from a box) into 4 groups: groups A, B and C with 20 subjects and group D with 5 
subjects. A ring with an identification code was applied to the right leg of each animal. 
Animals were then moved to cages (4 chickens/cage) until the end of the experiment. Water 
was provided ad libitum. Standard management practices were followed to keep animals free 
from stress.  
 
Groups A, B and C received levofloxacin at the dose rate of 5 mg/kg of body weight 
(Levofoxacin Kabi 5 mg/ml, Fresenius Kabi, Verona, Italy) according to a randomized, 
parallel study design. Group D received saline solution at the same volume as the drug. After 
overnight fasting, groups A and B received levofloxacin orally directly into the chickens' 
crop using an 18-gauge metal ball-tipped gavage connected to a 2.5 ml syringe. Group C 
received the drug intravenously through the vein of the right wing using a 2.5 ml syringe and 
26- gauge needle. Although poultry are not usually medicated via the IV route, this was 
necessary to calculate key PK parameters such as absolute CL and absolute oral 
bioavailability, these values allow for calculation of optimal dose. Group D received saline 
solution by oral administration via the same method as groups A and B. Concerning blood 
collections, samples (0.7 ml) were collected from groups A and C at time 0 (prior drug 
administration) 5, 30 min, and 1, 4, 6, 8, 10, 24, 48 h using an IV catheter (24Gx25mm, BD 
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Venflon, Milan, Italy) fixed into the left wing vein. After centrifugation at 400xg for 10 min, 
plasma and serum were separated and split into two aliquots, for PK and PD analysis, 
respectively, and stored at -20 °C until use within 30 days of collection. Animals in group B 
were divided into 5 sub-groups (n = 4) and euthanized through cervical dislocation at 1, 6, 10, 
24 and 48 h after drug administration for organ collection. Pectoralis muscle, liver, lungs and 
kidney were separated from each carcass, promptly washed in saline and stored at -80 °C 
until analysis. To provide control blood and organs for analytical purposes, animals in group 
D (control group) were bled and organs collected at 1, 6, 10, 24 and 48 h (one animal for 
each time point). 
 
Preparation of solutions 
Singular stock solutions of levofloxacin and IS in MeOH were prepared using 
volumetric flasks at the concentration of 1000 μg/ml and were stored at -20 °C. To reach a 
final concentration of 100 μg/ml, appropriate dilutions of stock standard solutions were 
prepared by diluting 1 ml of each solution to 10 ml. Levofloxacin solution was diluted in 
glass tubes (10 ml) to reach final concentrations of 5, 2 and 1 μg/ml and were stored at 4 °C. 
These last concentrations were then diluted to prepare a 6-point calibration curve at the 
following concentrations 5, 1, 0.500, 0.250, 0.100, 0.050 μg/ml and 2, 1, 0.500, 0.250, 0.100, 
0.050 μg/ml, of levofloxacin in plasma and organs respectively. The analyte was stable for at 
least 10 weeks if stored at 4 °C. 
 
Instrumentation and chromatographic conditions 
The HPLC system was an LC system (Jasco Inc., Easton, Maryland, USA) consisting 
of a high-pressure mixer pump (model PU 980 Plus), spectrofluorometric detector (model 
2020 Plus), and a loop of 50 μl. Data were processed using Borwin software (Jasco Inc., 
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Easton, Maryland, USA). Chromatographic separation assay, based on a method previously 
described by Giorgi et al. (2013) with slight modifications, was performed using a Gemini 
C18 analytical column (250 x 4.6-mm inner diameter, 5-μm particle size, Phenomenex, 
Torrance, California, USA) maintained at 25 °C. The mobile phase consisted of acetonitrile: 
aqueous solution (20:80, v/v%) at a flow rate of 1ml/min. 
 
The aqueous solution consisted of potassium dihydrogen phosphate (0.02 M), and 860 
µl of tetraethylamine (0.012 M) in water adjusted to pH 4 with orthophosphoric acid (0.006 
M). Excitation and emission wavelengths were set at 295 and 490 nm, respectively. 
 
Sample preparation 
The procedure of levofloxacin extraction from plasma and organs was based on that 
previously reported by Giorgi et al. (2013) with slight modifications. 
 
Plasma extraction 
Aliquots (0.2 ml) of plasma were added to 0.1 ml of IS (10 µg/ml) diluted with 800 
ml of 0.1M phosphate buffer at pH 7.1. After adding 4 ml of a mixture of trichloromethane: 
isopropanol (5:1 v/v), the samples were shaken at 200 oscillations/min for 10 min and 
centrifuged at 4000 x g for 5 min. Three ml of the organic layer was transferred into a clean 
tube and dried at 40 ° C under nitrogen stream. The residue was dissolved in 0.2 ml MeOH, 
vortexed, and an aliquot was injected onto the chromatographic system. 
 
Organs extractions 
Liver, kidney, lungs and muscle were thawed and immediately dissected into small 
pieces. A total of 1 g per sample was placed into 10 ml glass tubes and was added to 3 ml of 
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homogenization reagent consisting of 0.1M phosphate buffer at pH 7.1. The suspension was 
homogenized using an Ultra Turrax for 30 sec. Internal standard aliquots of 0.1 ml of IS (10 
µg/ml) was added to 500 µl of suspension and vortexed for 1 min. Four ml of a mixture of 
trichloromethane: isopropanol (5:1 v/v) was added and the samples were shaken at 200 
oscillations/min for 10 min and centrifuged at 4000 x g for 5 min. Three ml of the organic 
layer was transferred into a clean tube and dried at 40°C under nitrogen stream. The residue 
was dissolved in 0.2 ml MeOH, vortexed, and an aliquot was injected onto the 
chromatographic system. 
 
Quantification 
Standard curves were constructed with standard levofloxacin concentrations vs. ratio 
of levofloxacin/internal standard peak areas. Linearity of the regression curves in the range 
50-5000 ng/ml and 50-2000 ng/ml for plasma and organs respectively were assessed on the 
basis of the residual plot, the fit test and the back calculation (within 20% of known amount). 
Limit of detection (LOD) and limit of quantitation (LOQ) were determined as analyte 
concentrations giving signal-to-noise ratios of 3 and 10, respectively. The quantitative HPLC 
method for plasma and each organ were validated by examining the measurement of 
consistency of results (within-run and between-run), correlation (coefficient of determination 
of the standard curve), and extraction efficiency of the assay. The within-run precision was 
calculated from similar responses from six repeats of three control samples (10, 500, and 
1000 ng/ml) in one run. The between-run precision was determined by comparing the 
calculated response (in ng/ml back-fit of the standard curve) of the low (10 ng/ml), middle 
(500 ng/ml), and high (1000 ng/ml) control samples over three consecutive daily runs (total 
of six runs). The assay accuracy for within-run and between-run was established by 
determining the ratio of calculated response to expected response for low (10 ng/ml), middle 
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(500 ng/ml), and high (1000 ng/ml) control samples over six runs. The extraction efficiency 
was determined by comparing the response (in area) of low, middle, and high standards, and 
the internal standard, spiked into blank plasma eluent before evaporation, to the response 
from equivalent extracted standards. 
 
Pharmacokinetic analysis 
PK parameters for intravenous and oral administration were determined individually 
as a non-compartmental model using WinNonlin 5.3.1 software (Pharsight, Princeton, New 
Jersey, USA). The maximal concentration (Cmax) and time to reach maximal concentration 
(Tmax) were determined from the raw data. The elimination rate constant (z) was estimated 
by semi-log lineal regression of the terminal slope, and elimination half-life (HLz) was 
estimated by ln2/z. Area under the plasma vs time curve (AUC) and area under the first 
moment curve (AUMC) were calculated from 0 to the last quantifiable concentration using a 
linear trapezoidal method. Mean residence time (MRT) was calculated as AUMC/AUC. For 
intravenous administration, total plasma clearance (Cl) and volume of distribution during the 
terminal phase (Vd) were determined by the equations: 
Cl =                       
Vd =         
The oral bioavailability (F) was calculated as: 
F =                       
The differences between the AUC0-last and AUC0-∞ were always lower than 20% 
 
Serum protein binding 
The ultrafiltration method was used according to Whitlam and Kenneth (1981). Five 
ranges of levofloxacin concentrations (10, 50, 100, 500, 1000 ng/ml) were used to determine 
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the percentage of binding. Each experiment was run in triplicate. The EMIT free level filter 
system (Syva Co., Palo Alto, California, USA) was used for the ultrafiltration. One ml of 
serum spiked with various concentrations of levofloxacin was placed in the filter. The 
samples were centrifuged for 10 min at 2000 x g, 37 °C. The obtained ultra-filtrate containing 
free levofloxacin underwent HPLC analysis.  
 
Isolation of Escherichia coli 
Two field Escherichia coli isolates were collected from cloacal swabs of healthy 
broiler chickens. Animals were housed in a poultry farm near Turin (Italy) and no 
pharmacological treatments had been administered in the previous two months. The samples 
were cultured on Mac Conkey agar (Oxoid, Milan, Italy) and incubated at 37 °C overnight. 
Lactose-fermenting, indole-positive colonies were evaluated using the BBL Crystal test 
(Becton Dickinson, Milan, Italy). Then, the identified E. coli colonies were stored in Luria-
Bertani broth (Oxoid, Milan, Italy) containing 15% glycerol at -80 °C until further testing. 
American Type Culture Collection (ATCC, Virginia, USA) strain of E. coli 25922 was also 
used in this study as reference strain.  
 
Determination of MIC and MBC values in broth and in serum 
Minimal inhibitory concentration (MIC) was determined in broth and in serum 
obtained from healthy broiler chickens using the microdilution method according to Clinical 
and Laboratory Standards Institute (CLSI) guidelines (CLSI, 2009). Briefly, E. coli strains 
were seeded on Trypticase Soy Agar (TSA) (Oxoid, Milan, Italy). Colonies following 
overnight growth were directly suspended in Mueller-Hinton broth (MHB) (Oxoid, Milan, 
Italy) to obtain a turbidity comparable to the McFarland turbidity standard of 0.5. Cultures 
were diluted 1:100 with broth to reach a final concentration of 10
6
 colony forming units 
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(CFU)/ml. Levofloxacin solution (final concentration of 64 μg/ml) was added either to MHB 
or to serum obtained from the control broiler chickens. Serial dilutions from this solution 
were prepared in broth and in serum to reach concentrations ranging from 32 μg/ml to 0.008 
μg/ml, and in presence of approximately 5×105 CFU/ml. Plates were incubated at 37 °C for 
18 h and read at 600 nm, using the Ultraspec 2000 Spectrophotometer (Pharmacia Biotech, 
Milan, Italy). The MIC was reported as the lowest concentration of tested drug able to inhibit 
bacterial growth. From the wells showing no visible sign of growth/turbidity during MIC 
determination, bacteria were transferred into TSA plates by the streak plate method. The 
plates were then incubated at 37 °C for 24 h. The smallest concentration showing no growth 
of tested organisms was considered as the minimum bactericidal concentration (MBC). MIC 
and MBC of levofloxacin against E. coli ATCC 25922 were only determined in MHB, 
whereas the same parameters were evaluated for the sensitive field strains in both MHB and 
serum. All experiments were performed in triplicate. 
 
In vitro bacterial killing curves 
Twenty blood samples were obtained from untreated healthy broiler chickens. The 
animal samples were collected from a poultry farm near Turin (Italy). Samples were collected 
prior to slaughter. Blood samples were kept at room temperature for 60 min and then 
centrifuged at 2000 x g for 10 min, and immediately frozen at −20  °C until further analysis. 
 
Eight colonies from 24 h TSA culture of the sensitive field E. coli strains were 
suspended in 9 ml MHB and incubated for 20 h at 37 °C. Solutions of levofloxacin in serum 
(1 ml) were prepared at the following concentrations: 0.0 μg/ml (control), 0.03 μg/ml, 0.06 
μg/ml, 0.125 μg/ml, 0.25 μg/ml, 0.5 μg/ml, and 1 μg/ml. These solutions were added to 10 μl 
broth culture in order to reach the final concentration of approximately 2×10
7
 CFU/ml. To 
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determinate colony forming units, serial dilutions from 10
–2
 tо 10–6 in sterile saline were 
prepared (control = 10
–8
) and were incubated for 3, 6 and 24 h at 37 °C. Then, 10 μl of each 
dilution were inoculated on TSA and colony-forming units were counted after 16 h. The 
countable dilution is the dilution that gives 3 to 30 colonies per 10 µl drop of sample 
dispensed (Herigstad et al., 2001). All experiments were performed in triplicate. 
 
Ex vivo bacterial killing curves 
Eight to ten colonies from overnight growth of E. coli in TSA (as described above) 
were used to inoculate 9 ml of MHB, and then incubated overnight at 37 °C. To each 0.5 ml 
serum sample from treated animals, 5 µl of the stationary-phase bacterial culture was added 
to give a final concentration of approximately 3×10
7
 CFU/ml. To determine the numbers of 
CFU, serial dilutions (ranging from 10
-2
 to 10
–6
) were prepared with sterile saline and 
incubated at 37 °C for 3, 6, and 24 h. Thereafter, aliquots of 10 µl were plotted on TSA plates 
and the numbers of CFU were counted after 16 h incubations. The countable dilution is the 
dilution that gives 3 to 30 colonies per 10 µl drop of sample dispensed (Herigstad et al., 
2001). All experiments were performed in triplicate. 
 
PK/PD integration and optimal dose determination 
For PK/PD integration, the indices, in vivo Cmax/MIC and AUC24h/MIC, were 
calculated by linking PK data with PD index (MIC) for serum after oral administration of 
levofloxacin in clinically isolated E. coli. 
 
For PK/PD modeling, ex vivo AUC24h/MIC were obtained after 24h incubation from 
ex vivo time killing curve and fitted using the sigmoidal inhibitory Emax model and the 
following equation: 
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                             〖  〗              
where Emax is the log10 difference in bacterial counts in the test sample containing 
levofloxacin after 24 h of incubation when the limit of detection is reached; E0 is the log10 
difference in bacterial counts in the control sample (without treatment) after 24 h incubation 
compared to the initial inocula log10 count in samples incubated between time 0 and 24 h; Ce 
is the ex vivo AUC24h/MIC in the effect compartment; and N is the Hill coefficient which 
describes the steepness of the ex vivo AUC24h/MIC-effect curve. These PD indices were 
calculated using a non-linear regression software (WinNonlin, Princeton, New Jersey, USA). 
 
The antibacterial effect of levofloxacin was quantified from the sigmoidal inhibitory 
Emax model for three levels of growth inhibition: bacteriostatic (no change in bacterial count 
from control zero time count), bactericidal effect (99.9% reduction in bacterial count) and 
bacterial eradication (the lowest ex vivo AUC24h/MIC that produced a reduction in bacterial 
counts to the limit of detection). Thus, the values of ex vivo AUC24h/MIC for bacteriostatic 
and bactericidal effect were the values which produce E = 0 and -3, respectively. 
 
Using PK/PD modelling, the optimal oral dose in broilers was predicted and 
calculated using the following equation (McKellar et al., 2004): 
                         〖   〗                         
where Cl is the clearance; ex vivo AUC24h/MIC is the ex vivo AUC24h/MIC ratio for optimal 
efficacy; F is the bioavailability; MIC is the minimum inhibitory concentration; fu is the free 
fraction of drug in plasma. 
 
Statistical analysis 
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PK and PD data were expressed as mean ± SD, except for PK/PD indices which were 
presented as mean ± SE. Statistical comparison of PK parameters was determined with 
Student’s t-test and performed by Excel program (Microsoft, Redmond, Washington, USA). 
 
Results 
MIC and MBC determination 
The results from the determination of MIC in MHB showed that the two field E. coli 
isolates were sensitive to levofloxacin. MIC and MBC values are summarized in Table 1. The 
MICs of levofloxacin in MHB and serum were 0.03 μg/ml and 0.06 µg/ml, respectively. 
MBCs in MHB and serum were 0.03 and 0.125 μg/ml, respectively.  
 
Pharmacokinetics of levofloxacin 
No adverse effects were observed during the experiment. Following IV and PO 
administration of levofloxacin at 5 mg/kg, the plasma concentration vs. time curve is 
illustrated in Fig 1. Levofloxacin concentration following IV and PO administration were 
detectable in the plasma up to 24. PK parameters of levofloxacin were presented in Table 2. 
After a PO administration, levofloxacin showed rapid absorption with the mean Tmax value of 
0.88 h. The mean values of HLλZ for IV and PO were 6.93 and 8.09 h, respectively, but this 
difference was not statistically significant. MRT was also consistent between the two groups. 
The bioavailability for PO administration was complete with a mean value of 123.25%. 
 
Disposition of levofloxacin in tissues 
Levofloxacin residues were found in the investigated tissues up to 48 h following oral 
administration at 5 mg/kg (Fig 2). At 1 h after oral administration, tissue drug concentrations 
in most organs were high and then decreased over time except in muscle. Maximum 
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concentration in muscle was reached at 6 h after administration. The highest levels of 
levofloxacin (6576 ± 1741 ng/ml) were observed in the liver. The concentrations of 
levofloxacin in kidney, lungs and muscle were the next highest. The levels of levofloxacin 
were similar in liver and kidney, and higher than those in muscle and lung. 
 
Serum protein bound 
Levofloxacin is approximately 20 to 30% bound to serum proteins. The average value was 24 
± 5%.  
 
In vitro bacterial killing curves 
In vitro bacterial activities of levofloxacin against E. coli is presented in Fig3A. The 
number of bacteria in the control sample increased by ~5 log10 CFU/ml after 24 h incubation. 
For 1/2 MIC and MIC treatment, the growth of bacteria was reduced up to 6 h, after that a 
slight increase in growth was visible. At 2 MIC, the number of bacteria decreased in count to 
>3 log10 CFU/ml after 3 h exposure, it then reduced below the limit of detection. 
Concentrations ranging from 4 to16 MIC showed bacterial eradication after 3 h of exposure. 
 
Ex vivo bacterial killing curves 
The ex vivo antibacterial activity of levofloxacin against sensitive field E. coli was 
determined using serum samples collected at different time points (10, 30 min, 1, 4, 6, 10, 24 
and 48 h), these corresponded to mean levofloxacin concentrations of 841, 1591, 2135, 981, 
651, 329, 137 and 27 ng/ml, respectively. The ex vivo time killing curves are presented in Fig. 
3B. Ex vivo antibacterial effect of levofloxacin was similar to the in vitro time killing curve, 
this indicated that a levofloxacin concentration above 2MIC lead to eradication of E. coli 
after 24 h of incubation. In the lowest plasma concentration sample (48 h), the number of 
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bacteria remained stable at the 3 h incubation time point, then, the level of bacteria increased 
in amount so it was similar to that of the control sample after 6 h. All the other tested samples, 
ranging from 10 min to 10 h, demonstrated a high bactericidal effect, that started after 3 h of 
incubation and was maintained for the entire experiment. The 24 h samples demonstrated 
efficiency after 6 h of incubation till the end of the experiment.  
 
PK/PD integration 
The mean values of in vivo Cmax/MIC, AUC24h/MIC, Cmax/MBC and AUC24h/MBC 
against E. coli are represented in Table 3. After oral administration of levofloxacin, in vivo 
Cmax/MIC and AUC24h/MIC obtained against E. coli were 32.48 and 261.59 h, respectively. 
Also, the mean values for in vivo Cmax/MBC and AUC24h/MBC were 15.59 and 125.56 h, 
respectively. 
 
PK/PD modelling and optimal dose determination 
The PK/PD indices obtained from the Emax model are presented in Table 4. The mean 
values of ex vivo AUC24h/MIC corresponding to bacteriostatic, bactericidal and eradication 
effects were 18.77, 24.02 and 36.27 h, respectively. The slope of Emax model was steep with 
mean N value of 5.21. 
 
Based on the obtained ex vivo AUC24h/MIC by PK-PD modelling, the daily optimal 
dose of levofloxacin corresponding to bacteriostatic, bactericidal and eradication effects was 
determined. The MIC90 values (range from 0.06 to 0.125 µg/ml) of levofloxacin against E. 
coli were sourced from the literature for the determination of optimal dose (Hansen and 
Blondeau, 2005). Optimal doses for the expected antibacterial effects are presented in Table 5. 
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Discussion 
It has been widely recognized that inappropriate usage, including over- and misuse of 
antibiotics, is a risk factor for both emergence of resistance and therapeutic failure. Thus, the 
appropriate dosage should be determined, not only to maximize clinical efficacy, but also to 
minimize the emergence of resistance for target animal species (Schentag, 2000; Dagan et al., 
2001; Toutain et al., 2002). The PK/PD approach is considered a proven tool in the design of 
optimal dosage strategies. In addition, PK/PD modelling of time–kill curves has the 
advantage of describing the PD effect by parameters, which represent the potency and 
efficacy of drug. Data on the PK/PD of levofloxacin in poultry are limited, and, to the authors’ 
knowledge, this is the first complete study that considers PK/PD of levofloxacin in broilers. 
 
After IV and PO administration of levofloxacin to broilers, the mean half-life values 
for IV and PO groups were 6.93 and 8.09 h, respectively, which are longer than those 
reported in sheep (Patel et al., 2012), camels (Goudah, 2009), goats (Goudah et al., 2009) and 
calves (Kumar et al., 2012), but shorter than those in cats (Albarellos et al., 2005). These data 
indicate that levofloxacin shows some difference in elimination rate among animal species. 
However, these findings are not consistent with data reported in the study of Varia et al (2009) 
in which levofloxacin was administered at 10 mg/kg in broilers. These differences may 
potentially be explained by experimental discrepancies of dosage, age, breed and number of 
animals between the two studies. 
 
The apparent volume of distribution at steady state (Vss) was 2881 ml/kg in broilers 
indicating a relatively wide distribution and it was higher than that reported in sheep (Patel et 
al., 2012), camels (Goudah, 2009), goats (Goudah et al., 2009) and cats (Albarellos et al., 
2005). Also it was consistent with that reported in broilers (Varia et al., 2009). Levofloxacin 
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is eliminated primarily by the kidney with the involvement of both glomerular filtration and 
tubular secretion (Fish and Chow, 1997). The CL (mean value; 381.17 ml/hr/kg) in broilers 
was similar to those observed in calves (Kumar et al., 2012), sheep (Patel et al., 2012) and 
camels (Goudah, 2009). 
 
The absolute bioavailability of levofloxacin in broilers after PO administration was 
almost complete with mean %F value (123.25%) indicating the excellent absorption of 
levofloxacin in broilers. However, variation in bioavailability has been found among animal 
species. This value was similar to that measured in camels (94%, Goudah, 2009), but higher 
than those observed in calves (62%, Kumar et al., 2012; 57%, Dumka and Srivastava, 2006; 
2007), and cats (71%, Albarellos et al., 2005). 
 
Following PO administration of levofloxacin at the dose of 5 mg/kg, the drug 
concentration in liver was 6.57±1.74 μg/g after 1 h and 0.14±0.01 μg/g after 48 h respectively, 
whereas in muscles the concentration was 0.94±0.07 μg/g after 1 h and 0.04±0.01 μg/g after 
48 h respectively. This persistence of drug in tissue supports the wide value for Vss found in 
this investigation. The levels of levofloxacin in liver and kidney were higher (4-5 folds) than 
those measured in muscle and lungs 1 h after administration. This might suggest a specific 
levofloxacin affinity for these two clearing organs. 
 
The PK/PD approach allows determination of the optimal dosage on the basis of the 
microbiological susceptibility and the variation in disposition kinetics (Hyatt et al., 1995; 
Sanchez- Recio et al., 2000; Toutain and Bousquet-Melou, 2006). In defining PK/PD 
relationships the key parameters of PKs are the area under the plasma concentration curve 
(AUC), the maximum plasma concentration (Cmax) and the duration of plasma concentration 
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exceeding the MIC (T>MIC) (Hyatt et al., 1995). The key PD parameter is the minimum 
inhibitory concentration (MIC) (Hyatt et al., 1995). Although the methods for MIC are 
standardized and reproducible (CLSI, 2009), the results of this method may be influenced by 
many technical factors (inoculum size, incubation times, medium content, etc.) (Hyatt et al., 
1995). Significant differences in MIC or MBC values both in broth and serum have been 
found in many investigations (Aliabadi and Lees, 2001; Hyatt et al., 1995). In the present 
investigation, MIC and MBC of levofloxacin against E. coli were determined in broth and 
serum of broilers to overcome this limitation. MIC (0.03MHB–0.06serum μg/ml) and MBC 
(0.03MHB –0.125serum μg/ml) were significantly different in both matrices. This result indicates 
that the serum inhibitory activity was reduced and that corresponds with previous data 
demonstrating the decreased antimicrobial effects of most fluoroquinolones in serum (two- to 
four-fold higher MICs) (Aliabadi et al., 2003a; Aliabadi et al., 2003b; Haritova et al., 2004). 
This result may be accounted for by the moderate protein binding of levofloxacin reported in 
humans (38%, Fish and Chow, 1997) and in buffalo (19%, Ram et al., 2008). The protein 
binding of levofloxacin in broilers determined in this investigation was in between those 
previously reported, but still in the same range. 
 
Data from the time killing curve indicates that levofloxacin showed concentration-
dependent killing pattern against E. coli. For E. coli, levofloxacin produced an in vitro 
antibacterial activity with low multiples (2- and 4-) of MIC in serum. The bactericidal 
activity rapidly manifested within 3-6 h of incubation, followed by eradication with 4 MIC at 
3 h. The elimination of bacteria was maintained up to 24 h of incubation (where drug 
concentration > 2 MIC). Ex vivo antibacterial activity was consistent with in vitro time killing 
curve data that indicated levofloxacin concentrations ≥2 MIC lead to eradication of E. coli. 
To the author’s knowledge, this is the first paper reporting this comparison. 
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According to Hyatt et al. (1995), in quantitative terms the PK/PD parameters which 
have been most extensively investigated, and for which the most robust information is 
currently available, are AUC24/MIC, Cmax/MIC and T > MIC. AUC24h/MIC and Cmax/MIC 
are the best predictor of efficacy correlating with concentration-dependent antibiotics (Craig, 
1993; McKellar et al., 2004). It has been widely proposed that dosage regimens which 
produce high PK/PD parameters such as AUC24h/MIC > 125 and Cmax/MIC > 10, are more 
likely to be successful and less likely to be associated with emergence of resistance (Forrest 
et al., 1993; Schentag, 2000). However, more recent studies suggested that these values might 
be overestimated and should be lowered in veterinary medicine (Papich, 2014). The 
calculated mean Cmax/MIC and AUC24h/MIC for levofloxacin in this study were 32 and 262, 
respectively. According to the concept outlined above, the dose of 5mg/kg/day PO in broilers 
seems to be effective for the treatment of colibacillosis. 
 
In addition, in vitro MIC method using artificial growth media are limited by the lack 
of various host factors such as their immune function. To address this limitation, integration 
of PD to PK in an ex vivo model was attempted in this study. The ex vivo AUC24/MIC 
parameters were utilised for this integration using the sigmoid Emax model with the reduction 
in bacterial numbers after 24 h of incubation. The lowest effective ex vivo AUC24/MICs, 
corresponding to bacteriostatic, bactericidal activity and eradication of the bacteria, were 
determined for serum. The mean values of ex vivo AUC24/MIC corresponding to 
bacteriostatic, bactericidal and eradication effects were 18.77, 24.02 and 36.27 h, respectively. 
The optimal dosages corresponding to bacteriostatic, bactericidal activity and eradication of 
the bacteria were predicted by using the ex vivo AUC24/MIC. The calculated optimal doses 
for bacteriostatic, bactericidal activity and eradication were 1.1, 1.4 and 2.1 mg/kg, 
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respectively, considering MIC90 of 0.06 µg/ml. However, using recently reported MIC90 
(0.125 µg/ml) of E. coli the predicted doses were 2.2, 2.9 and 4.3 mg/kg/day PO, respectively. 
 
Conclusion 
This is the first study to assess the PK/PD relationship of levofloxacin in broilers. 
PK/PD indices against E. coli were investigated in an ex vivo model. The data presented 
would suggest optimal doses of 2.9 to 4.3 mg/kg/day PO for levofloxacin against E. coli if 
the MIC is 0.125 µg/ml. Thus, further studies are needed to determine the efficacy in 
naturally diseased animals or disease models. 
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Table 1  
Minimal inhibitory concentrations (MICs), minimal bactericidal concentrations (MBCs) for 
field Escherichia coli isolates and the reference E. coli ATCC 25922 strain. 
 
E. coli strain 
MIC μg/ml MBC μg/ml 
MHB Serum MHB Serum 
Sensitive E. coli A 0.03 0.06 0.03 0.125 
Sensitive E. coli B 0.03 0.06 0.03 0.125 
E. coli ATCC 25922 0.015 - 0.03 - 
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Table 2 
Pharmacokinetic parameters of levofloxacin after IV and PO administration at 5 mg/kg in 
broilers. 
 
Parameters Units IV PO 
Mean  SD Mean  SD 
R
2
  0.99 ± 0.02 0.97 ± 0.04 
λZ 1/h 0.12 ± 0.04 0.09 ± 0.02 
HLλZ h 6.93 ± 2.94 8.09 ± 1.71 
Tmax h  ± / 0.88 ± 0.23 
Cmax ng/ml  ± / 1949 ± 382 
C0 ng/ml 3543 ± 2278 / ± / 
AUC0-24 h*ng/ml 12734 ± 3772 15695 ± 1464 
Vss ml/kg 2881 ± 1071 /  / 
V
§
 ml/kg 3599 ± 1335 3288 ± 659 
CL
§
 ml/h/kg 381.17 ± 90.10 282.69 ± 26.42 
AUMC h*h*ng/ml 68569
a
 ± 27012 108156 ± 9980 
MRT h 5.37 ± 1.31 6.90 ± 0.37 
F % / ± / 123.25 ± NA 
λZ, first-order rate constant; HLλZ, half-life of the terminal portion of the curve; Tmax, time at 
the maximum drug concentration; Cmax, maximum plasma drug concentration; C0, 
concentration at time 0; AUC0-24, area under the curve from 0 to the last; Vss, volume of 
distribution at steady state; V/F, volume of distribution during the elimination phase; CL/F, 
body clearance during the elimination phase; AUMC, area under the first moment curve from 
0 to the last; MRT, mean residence time; F, absolute bioavailability. NA, not assessable.  
§
,this value is divided for its F% in the PO group. 
a
, significant difference between each treatment group (P<0.05). 
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Table 3 
Indices of PK/PD integration after PO administration of levofloxacin at 5 mg/kg in broilers. 
 
 Parameters Units Mean ± SD 
 Cmax/MIC - 32.48 ± 6.37 
 AUC24h/MIC h 261.59 ± 24.41 
 Cmax/MBC - 15.59 ± 3.06 
 AUC24h/MBC h 125.56 ± 11.71 
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Table 4 
Parameters of PK/PD modelling from ex vivo experiments after oral administration of 
levofloxacin at 5 mg/kg in broilers. 
Parameters Units Mean ± SD 
Log10 Emax CFU/ml -6.65 ± 0.18 
Log10 E0 CFU/ml 3.35 ± 0.08 
Log10 Emax-E0 CFU/ml -10.01 ± 0.21 
EC50 h 21.46 ± 6.94 
AUC24h/MIC for bacteriostatic effect h 18.77 ± 0.12 
AUC24h/MIC for bactericidal effect h 24.02 ± 0.28 
AUC24h/MIC for bacterial eradication h 36.27 ± 0.88 
Slope (N) - 5.21 ± 0.83 
E0, difference in bacterial count in control sample between time 0 and 24 h; Emax, difference 
in bacterial count in sample incubated with levofloxacin between time 0 and 24 h, when the 
detection limit is reached; EC50, AUC24h/MIC of drug producing 50% of the maximum 
antibacterial effect; N, slope of the AUC24h/MIC – response curve. 
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Table 5 
Predicted optimal daily dose of levofloxacin for PO administration in broilers. 
Expected effects 
a
MIC90: 0.06 µg/ml 
a
MIC90: 0.125 µg/ml 
Dose for bacteriostatic effect 1.1 mg/kg 2.2 mg/kg 
Dose for bactericidal effect 1.4 mg/kg 2.9 mg/kg 
Dose for eradication 2.1 mg/kg 4.3 mg/kg 
a
 MIC90 values from a literature (Hansen and Blondeau, 2005).  
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Figure legends 
 
Fig. 1. Mean plasma concentration vs. time curve of levofloxacin after IV (——) and PO (-
-□--) administrations at 5 mg/kg in broilers. Bars represent the SD. 
 
Fig. 2. Tissue disposition of levofloxacin after PO administration at 5 mg/kg in broilers. Bars 
represent the SD. 
 
Fig. 3. In vitro (A) and ex vivo (B) antibacterial effects of levofloxacin in serum of broilers 
against E. coli after PO administration at 5 mg/kg. 
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Figure 1 
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Figure 3 
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Highlights 
 MIC of levofloxacin in wild E.coli: 0.03 μg/ml and 0.06 µg/ml in MHB and serum. 
 MBC in MHB and serum: 0.03 and 0.125 μg/ml, respectively.  
 Mean values of terminal half-life for IV and PO groups: 6.93 and 8.09 h.  
 PO administration: the peak plasma concentration was achieved at 0.88 h (Tmax). 
 Mean value of oral bioavailability was 123.25%. 
 Levofloxacin was found in tissues up to 48 h following PO administration at 5 mg/kg. 
 PK/PD integrated results suggest that 5 mg/kg is an effective dose to kill E.Coli. 
 Levofloxacin was deposited in liver and kidney with high concentration. 
 Predicted maximum antibacterial effect (Emax): 10
-6.65
 CFU/ml. 
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